Biogen's (BIIB) Immunology Bet Meets A Pricier Balance Sheet
On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026.







